Results 61 to 70 of about 191,459 (192)

Direct comparison of nocebo, deceptive placebo and open-label placebo effects on sustained visual attention

Acta Psychologica
Positive and negative expectations crucially shape how we perceive our surroundings, including our emotional and cognitive abilities. Prior work shows that cognitive abilities in different domains can be modulated by placebo or nocebo effects, in ...
Jonas Potthoff, Helena Hartmann
doaj   +1 more source

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

BMC Psychiatry, 2005
Background Although serotonin reuptake inhibitors are effective in the treatment of OCD, many patients fail to respond to these agents. Growing evidence from open-label and placebo-controlled trials suggests a role for augmentation of SRIs with atypical ...
van Ameringen Michael, Muller Jacqueline E, Seedat Soraya, Vythilingum Bavanisha, Carey Paul D, Stein Dan J   +5 more
doaj   +1 more source

Open-Label Placebo Trial among Japanese Patients with Chronic Low Back Pain [PDF]

Pain Research and Management, 2020
Background. The aim of this study was to confirm the effectiveness of open-label placebo (OLP) in Japanese patients with chronic low back pain (CLBP), similar to previous reports, and to investigate its short- and medium-term effects in this study population. Methods. Fifty-two patients with CLBP were randomized into a treatment as usual (TAU) group (n 
Tatsunori Ikemoto, Takefumi Ueno, Young-Chang Arai, Norimitsu Wakao, Atsuhiko Hirasawa, Kazuhiro Hayashi, Masataka Deie   +6 more
openaire   +3 more sources

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

Providing open-label placebos remotely—A randomized controlled trial in allergic rhinitis

PLOS ONE, 2021
Background Placebos can reduce physical symptoms even when provided with full honesty and disclosure. Yet, the precise mechanisms underlying the effects of “open-label placebos” (OLPs) have remained subject of debate. Furthermore, it is unclear whether OLPs are similarly effective when provided remotely, as is sometimes required e.g.
Tobias Kube, Verena E. Hofmann, Julia A. Glombiewski, Irving Kirsch   +3 more
openaire   +4 more sources

Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome. [PDF]

, 2020
BackgroundThe purpose of this study was to conduct a 20-week controlled trial of lovastatin (10 to 40 mg/day) in youth with fragile X syndrome (FXS) ages 10 to 17 years, combined with an open-label treatment of a parent-implemented language intervention (
Abbeduto, Leonard, Banasik, Amy, Bullard, Lauren, Hagerman, Randi, Kim, Kyoungmi, McDuffie, Andrea, Nguyen, Vivian, Potter, Laura A, Potter, Sarah Nelson, Tassone, Flora, Thurman, Angela John   +10 more
core  

Successful private–public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines [PDF]

, 2014
The European Paediatric Regulation mandated the European Commission to fund research on off-patent medicines with demonstrated therapeutic interest for children.
Baiardi, P, Bonifazi, D, Bonifazi, F, Ceci, A, Chiron, C, Davies, E H, Eichler, I, Felisi, M, Giannuzzi, V, Giaquinto, C, Jacqz-Aigrain, E, Neubert, A, on behalf of the GRiP Consortium,, Pressler, R, Rabe, H, Ruggieri, L, Turner, M A, Whitaker, M J   +17 more
core   +1 more source

Lennox-Gastaut Syndrome: A State of the Art Review. [PDF]

, 2017
Lennox-Gastaut syndrome (LGS) is a severe age-dependent epileptic encephalopathy usually with onset between 1 and 8 years of age. Functional neuroimaging studies recently introduced the concept of Lennox-Gastaut as "secondary network epilepsy" resulting ...
Mastrangelo, Mario
core   +1 more source

Open-label placebos enhance test performance and reduce anxiety in learner drivers: a randomized controlled trial

Scientific Reports
Passing the driving school test can be very challenging, especially in big cities, where up to 52% of all students fail this test. Consequently, many learner drivers experience stress and anxiety.
Michael Schaefer, Sören Enge
doaj   +1 more source

Placebos in the era of open‐label trials: An update for clinicians [PDF]

European Journal of Clinical Investigation, 2018
AbstractPlacebos have been used extensively by vast numbers of physicians, in a majority of clinical trials. Placebo effects involve behavioural, psychological and genetic factors and have been subject to ethical controversies stemming from the use of deception in treating patients.
Iftach Sagy, Jonathan Abres, Ariel Winnick, Alan Jotkowitz   +3 more
openaire   +2 more sources